nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—RET—autonomic nervous system—Gilles de la Tourette syndrome	0.122	0.126	CbGeAlD
Regorafenib—NTRK1—midbrain—Gilles de la Tourette syndrome	0.047	0.0485	CbGeAlD
Regorafenib—DDR2—nervous system—Gilles de la Tourette syndrome	0.0287	0.0296	CbGeAlD
Regorafenib—DDR2—central nervous system—Gilles de la Tourette syndrome	0.0276	0.0285	CbGeAlD
Regorafenib—MAPK11—nervous system—Gilles de la Tourette syndrome	0.0272	0.0281	CbGeAlD
Regorafenib—MAPK11—central nervous system—Gilles de la Tourette syndrome	0.0262	0.027	CbGeAlD
Regorafenib—BRAF—midbrain—Gilles de la Tourette syndrome	0.0247	0.0255	CbGeAlD
Regorafenib—DDR2—brain—Gilles de la Tourette syndrome	0.0219	0.0226	CbGeAlD
Regorafenib—FGFR1—midbrain—Gilles de la Tourette syndrome	0.021	0.0217	CbGeAlD
Regorafenib—MAPK11—brain—Gilles de la Tourette syndrome	0.0208	0.0215	CbGeAlD
Regorafenib—RET—midbrain—Gilles de la Tourette syndrome	0.0188	0.0194	CbGeAlD
Regorafenib—TEK—midbrain—Gilles de la Tourette syndrome	0.0171	0.0177	CbGeAlD
Regorafenib—FLT1—midbrain—Gilles de la Tourette syndrome	0.0165	0.0171	CbGeAlD
Regorafenib—RAF1—midbrain—Gilles de la Tourette syndrome	0.0164	0.017	CbGeAlD
Regorafenib—BRAF—brain—Gilles de la Tourette syndrome	0.0155	0.016	CbGeAlD
Regorafenib—RET—nervous system—Gilles de la Tourette syndrome	0.0154	0.0159	CbGeAlD
Regorafenib—RET—central nervous system—Gilles de la Tourette syndrome	0.0149	0.0153	CbGeAlD
Regorafenib—EPHX2—brain—Gilles de la Tourette syndrome	0.0148	0.0153	CbGeAlD
Regorafenib—FGFR2—nervous system—Gilles de la Tourette syndrome	0.0147	0.0151	CbGeAlD
Regorafenib—EPHA2—nervous system—Gilles de la Tourette syndrome	0.0144	0.0149	CbGeAlD
Regorafenib—FGFR2—central nervous system—Gilles de la Tourette syndrome	0.0141	0.0146	CbGeAlD
Regorafenib—TEK—nervous system—Gilles de la Tourette syndrome	0.0141	0.0145	CbGeAlD
Regorafenib—KDR—midbrain—Gilles de la Tourette syndrome	0.014	0.0144	CbGeAlD
Regorafenib—EPHA2—central nervous system—Gilles de la Tourette syndrome	0.0139	0.0143	CbGeAlD
Regorafenib—FLT1—nervous system—Gilles de la Tourette syndrome	0.0136	0.014	CbGeAlD
Regorafenib—TEK—central nervous system—Gilles de la Tourette syndrome	0.0135	0.014	CbGeAlD
Regorafenib—RAF1—nervous system—Gilles de la Tourette syndrome	0.0135	0.0139	CbGeAlD
Regorafenib—FLT4—brain—Gilles de la Tourette syndrome	0.0134	0.0138	CbGeAlD
Regorafenib—FGFR1—brain—Gilles de la Tourette syndrome	0.0132	0.0136	CbGeAlD
Regorafenib—FLT1—central nervous system—Gilles de la Tourette syndrome	0.0131	0.0135	CbGeAlD
Regorafenib—RAF1—central nervous system—Gilles de la Tourette syndrome	0.013	0.0134	CbGeAlD
Regorafenib—PDGFRA—nervous system—Gilles de la Tourette syndrome	0.0127	0.0131	CbGeAlD
Regorafenib—KIT—midbrain—Gilles de la Tourette syndrome	0.0124	0.0128	CbGeAlD
Regorafenib—PDGFRA—central nervous system—Gilles de la Tourette syndrome	0.0123	0.0127	CbGeAlD
Regorafenib—PDGFRB—midbrain—Gilles de la Tourette syndrome	0.0121	0.0125	CbGeAlD
Regorafenib—RET—brain—Gilles de la Tourette syndrome	0.0118	0.0122	CbGeAlD
Regorafenib—KDR—nervous system—Gilles de la Tourette syndrome	0.0115	0.0119	CbGeAlD
Regorafenib—FGFR2—brain—Gilles de la Tourette syndrome	0.0112	0.0116	CbGeAlD
Regorafenib—KDR—central nervous system—Gilles de la Tourette syndrome	0.0111	0.0114	CbGeAlD
Regorafenib—EPHA2—brain—Gilles de la Tourette syndrome	0.011	0.0114	CbGeAlD
Regorafenib—ABL1—midbrain—Gilles de la Tourette syndrome	0.0108	0.0111	CbGeAlD
Regorafenib—TEK—brain—Gilles de la Tourette syndrome	0.0107	0.0111	CbGeAlD
Regorafenib—FLT1—brain—Gilles de la Tourette syndrome	0.0104	0.0107	CbGeAlD
Regorafenib—RAF1—brain—Gilles de la Tourette syndrome	0.0103	0.0107	CbGeAlD
Regorafenib—KIT—nervous system—Gilles de la Tourette syndrome	0.0102	0.0105	CbGeAlD
Regorafenib—PDGFRB—nervous system—Gilles de la Tourette syndrome	0.00995	0.0103	CbGeAlD
Regorafenib—KIT—central nervous system—Gilles de la Tourette syndrome	0.0098	0.0101	CbGeAlD
Regorafenib—PDGFRA—brain—Gilles de la Tourette syndrome	0.00974	0.01	CbGeAlD
Regorafenib—PDGFRB—central nervous system—Gilles de la Tourette syndrome	0.00957	0.00988	CbGeAlD
Regorafenib—ABL1—nervous system—Gilles de la Tourette syndrome	0.00886	0.00915	CbGeAlD
Regorafenib—KDR—brain—Gilles de la Tourette syndrome	0.00878	0.00907	CbGeAlD
Regorafenib—ABL1—central nervous system—Gilles de la Tourette syndrome	0.00853	0.00881	CbGeAlD
Regorafenib—KIT—brain—Gilles de la Tourette syndrome	0.00778	0.00803	CbGeAlD
Regorafenib—PDGFRB—brain—Gilles de la Tourette syndrome	0.0076	0.00785	CbGeAlD
Regorafenib—ABCG2—midbrain—Gilles de la Tourette syndrome	0.0068	0.00702	CbGeAlD
Regorafenib—ABL1—brain—Gilles de la Tourette syndrome	0.00678	0.00699	CbGeAlD
Regorafenib—CYP2B6—nervous system—Gilles de la Tourette syndrome	0.00516	0.00532	CbGeAlD
Regorafenib—CYP2B6—central nervous system—Gilles de la Tourette syndrome	0.00496	0.00512	CbGeAlD
Regorafenib—DDR2—Extracellular matrix organization—COL27A1—Gilles de la Tourette syndrome	0.0048	0.154	CbGpPWpGaD
Regorafenib—CYP2C8—brain—Gilles de la Tourette syndrome	0.00439	0.00454	CbGeAlD
Regorafenib—ABCG2—brain—Gilles de la Tourette syndrome	0.00427	0.00441	CbGeAlD
Regorafenib—CYP2B6—brain—Gilles de la Tourette syndrome	0.00394	0.00407	CbGeAlD
Regorafenib—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00389	0.00402	CbGeAlD
Regorafenib—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00375	0.00387	CbGeAlD
Regorafenib—ABCB1—midbrain—Gilles de la Tourette syndrome	0.00335	0.00346	CbGeAlD
Regorafenib—RET—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00287	0.092	CbGpPWpGaD
Regorafenib—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00276	0.00285	CbGeAlD
Regorafenib—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.00265	0.00274	CbGeAlD
Regorafenib—ABCB1—brain—Gilles de la Tourette syndrome	0.00211	0.00217	CbGeAlD
Regorafenib—RET—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.00121	0.0388	CbGpPWpGaD
Regorafenib—EPHA2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.00118	0.0378	CbGpPWpGaD
Regorafenib—MAPK11—Parkinsons Disease Pathway—SLC6A3—Gilles de la Tourette syndrome	0.00109	0.035	CbGpPWpGaD
Regorafenib—KDR—Extracellular matrix organization—COL27A1—Gilles de la Tourette syndrome	0.00102	0.0327	CbGpPWpGaD
Regorafenib—EPHA2—Stabilization and expansion of the E-cadherin adherens junction—MET—Gilles de la Tourette syndrome	0.00102	0.0327	CbGpPWpGaD
Regorafenib—RAF1—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.000859	0.0276	CbGpPWpGaD
Regorafenib—KDR—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000746	0.0239	CbGpPWpGaD
Regorafenib—EPHA2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000613	0.0197	CbGpPWpGaD
Regorafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—MET—Gilles de la Tourette syndrome	0.000554	0.0178	CbGpPWpGaD
Regorafenib—RET—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000528	0.0169	CbGpPWpGaD
Regorafenib—RAF1—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.000501	0.0161	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000493	0.0158	CbGpPWpGaD
Regorafenib—FGFR2—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.000463	0.0149	CbGpPWpGaD
Regorafenib—FGFR1—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.000432	0.0139	CbGpPWpGaD
Regorafenib—MAPK11—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.00043	0.0138	CbGpPWpGaD
Regorafenib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000416	0.0133	CbGpPWpGaD
Regorafenib—EPHA2—Direct p53 effectors—MET—Gilles de la Tourette syndrome	0.000389	0.0125	CbGpPWpGaD
Regorafenib—NTRK1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000384	0.0123	CbGpPWpGaD
Regorafenib—EPHX2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000381	0.0122	CbGpPWpGaD
Regorafenib—NTRK1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000373	0.012	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000358	0.0115	CbGpPWpGaD
Regorafenib—NTRK1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000348	0.0112	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000332	0.0106	CbGpPWpGaD
Regorafenib—FLT1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000322	0.0103	CbGpPWpGaD
Regorafenib—ABL1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.000322	0.0103	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000309	0.00992	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000308	0.00989	CbGpPWpGaD
Regorafenib—RAF1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.000295	0.00945	CbGpPWpGaD
Regorafenib—BRAF—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000286	0.00917	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000278	0.00891	CbGpPWpGaD
Regorafenib—UGT1A1—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000262	0.00839	CbGpPWpGaD
Regorafenib—UGT1A9—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000262	0.00839	CbGpPWpGaD
Regorafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.000253	0.0081	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000248	0.00795	CbGpPWpGaD
Regorafenib—BRAF—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000219	0.00703	CbGpPWpGaD
Regorafenib—KDR—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000215	0.00688	CbGpPWpGaD
Regorafenib—EPHA2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000199	0.00637	CbGpPWpGaD
Regorafenib—RAF1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000198	0.00635	CbGpPWpGaD
Regorafenib—BRAF—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000183	0.00586	CbGpPWpGaD
Regorafenib—RAF1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000169	0.00543	CbGpPWpGaD
Regorafenib—PDGFRA—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000157	0.00505	CbGpPWpGaD
Regorafenib—RAF1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000152	0.00486	CbGpPWpGaD
Regorafenib—PDGFRB—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000142	0.00455	CbGpPWpGaD
Regorafenib—EPHA2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000142	0.00455	CbGpPWpGaD
Regorafenib—KDR—Axon guidance—MET—Gilles de la Tourette syndrome	0.00014	0.00449	CbGpPWpGaD
Regorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000129	0.00412	CbGpPWpGaD
Regorafenib—RAF1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000126	0.00406	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000119	0.0038	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000115	0.00369	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—HDC—Gilles de la Tourette syndrome	0.000113	0.00362	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000113	0.00362	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000107	0.00344	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000103	0.0033	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—MET—Gilles de la Tourette syndrome	9.99e-05	0.0032	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—HDC—Gilles de la Tourette syndrome	9.57e-05	0.00307	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—MET—Gilles de la Tourette syndrome	9.02e-05	0.00289	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	8.85e-05	0.00284	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—MET—Gilles de la Tourette syndrome	8.59e-05	0.00276	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	8.59e-05	0.00275	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—MET—Gilles de la Tourette syndrome	8.25e-05	0.00265	CbGpPWpGaD
Regorafenib—RAF1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	8.15e-05	0.00261	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8e-05	0.00257	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.51e-05	0.00241	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—MET—Gilles de la Tourette syndrome	7.35e-05	0.00236	CbGpPWpGaD
Regorafenib—ABCG2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	7.11e-05	0.00228	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	7.01e-05	0.00225	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—MET—Gilles de la Tourette syndrome	6.44e-05	0.00207	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.23e-05	0.002	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.05e-05	0.00194	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—HDC—Gilles de la Tourette syndrome	5.94e-05	0.0019	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—MET—Gilles de la Tourette syndrome	5.89e-05	0.00189	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.89e-05	0.00189	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.87e-05	0.00188	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.71e-05	0.00183	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.7e-05	0.00183	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.63e-05	0.00181	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.6e-05	0.0018	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.32e-05	0.00171	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.31e-05	0.0017	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	5.3e-05	0.0017	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	5.17e-05	0.00166	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.06e-05	0.00162	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.01e-05	0.00161	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.91e-05	0.00158	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.87e-05	0.00156	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	4.83e-05	0.00155	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.65e-05	0.00149	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.58e-05	0.00147	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.56e-05	0.00146	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.53e-05	0.00145	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.51e-05	0.00145	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.43e-05	0.00142	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.33e-05	0.00139	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.32e-05	0.00139	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.2e-05	0.00135	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.2e-05	0.00135	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.19e-05	0.00135	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.13e-05	0.00132	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.94e-05	0.00127	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.92e-05	0.00126	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.91e-05	0.00125	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.89e-05	0.00125	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	3.84e-05	0.00123	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.78e-05	0.00121	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.73e-05	0.0012	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.72e-05	0.00119	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.52e-05	0.00113	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.47e-05	0.00111	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.37e-05	0.00108	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.21e-05	0.00103	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	3.19e-05	0.00102	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.18e-05	0.00102	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.14e-05	0.00101	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.94e-05	0.000944	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.89e-05	0.000927	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.74e-05	0.00088	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.74e-05	0.000878	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.46e-05	0.000791	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.2e-05	0.000705	CbGpPWpGaD
